Go Pro
→ If you keep cash in a U.S. bank account… read this NOW (From Banyan Hill Publishing) (Ad)tc pixel
NASDAQ:DARE

Dare Bioscience Q2 2026 Earnings Report

Dare Bioscience logo
$1.34 0.00 (0.00%)
Closing price 08/5/2026 04:00 PM Eastern
Extended Trading
$1.32 -0.02 (-1.49%)
As of 08/5/2026 06:49 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
ProfileEarnings HistoryForecast

Dare Bioscience EPS Results

Actual EPS
N/A
Consensus EPS
-$0.30
Beat/Miss
N/A
One Year Ago EPS
N/A

Dare Bioscience Revenue Results

Actual Revenue
N/A
Expected Revenue
$0.00 million
Beat/Miss
N/A
YoY Revenue Growth
N/A

Dare Bioscience Announcement Details

Quarter
Q2 2026
Date
8/13/2026
Time
After Market Closes
Conference Call Date
Thursday, August 13, 2026
Conference Call Time
4:30PM ET

Conference Call Resources

Dare Bioscience Earnings Headlines

Daré Bioscience, Inc. (DARE) Discusses Women's Health Portfolio and Commercialization Highlights on Virtual Bus Tour Transcript
August 5 at 3:00 PM  |  seekingalpha.comhttps://seekingalpha.com/article/4931065-dare-bioscience-inc-dare-discusses-womens-health-portfolio-and-commercialization-highlights
Daré Bioscience Expands Access Options for DARE to PLAY™ and Specialized Menopause Care Through Strategic Collaboration with MyMenopauseRx
July 28, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/07/28/3334271/30757/en/dar%c3%a9-bioscience-expands-access-options-for-dare-to-play-and-specialized-menopause-care-through-strategic-collaboration-with-mymenopauserx.html
Nvidia's CEO says this small device is critical for AI growth
A tiny glass device smaller than a fingertip could redefine AI hardware. Nvidia CEO Jensen Huang calls it essential for AI to scale, while Sequoia Capital labels it a holy grail. Stocks tied to this technology have already surged 133 percent, 217 percent, and 320 percent in recent months, according to Brownstone Research analyst Jason Bodner, who identified Nvidia at 4.50.tc pixel
 |  Brownstone Research (Ad)
Daré Bioscience, Inc. (DARE) Discusses Women's Health Portfolio and Commercial Launches During Virtual Bus Tour Transcript
July 24, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4925028-dare-bioscience-inc-dare-discusses-womens-health-portfolio-and-commercial-launches-during
Dare Bioscience Stock Short Interest Report | NASDAQ:DARE | Benzinga
July 22, 2026  |  benzinga.comhttps://www.benzinga.com/quote/DARE/short-interest
Daré Bioscience Launches Nationwide Virtual Bus Tour Webinar Series to Showcase Commercial Strategy and Growth Opportunities
July 20, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/07/20/3329781/30757/en/dar%c3%a9-bioscience-launches-nationwide-virtual-bus-tour-webinar-series-to-showcase-commercial-strategy-and-growth-opportunities.html
See More Dare Bioscience Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Dare Bioscience? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Dare Bioscience and other key companies, straight to your email.

About Dare Bioscience

Dare Bioscience (NASDAQ:DARE) is a clinical-stage biopharmaceutical company focused on developing innovative therapies for women’s reproductive health. The company’s flagship development candidate is Ovaprene, a monthly, self-administered, non-hormonal contraceptive vaginal ring designed to offer an alternative to traditional hormone-based birth control methods. Through its proprietary intravaginal drug delivery platform, Dare seeks to address unmet medical needs in gynecology and contraception with products that prioritize efficacy, safety and ease of use.

In addition to its lead contraceptive program, Dare is advancing a pipeline of early-stage assets aimed at treating gynecologic conditions through local, non-systemic drug delivery. The company’s research strategy emphasizes platform versatility, enabling potential applications in areas such as mucosal immunization and topical therapies for vaginal health. Dare collaborates with academic institutions and strategic partners to leverage emerging technologies and expand its product opportunities within the women’s health market.

Headquartered in San Diego, California, Dare Bioscience operates in the United States and is listed on the Nasdaq Global Market under the ticker symbol DARE. The company is led by a management team with extensive experience in pharmaceutical development, regulatory affairs and commercial execution. Dare’s leadership is committed to advancing its clinical programs and delivering new options for women’s reproductive care.

View Dare Bioscience Profile
Earnings Tools